How Low Can Pharmaceutical HLDRS (AMEX: PPH) Go? Asks Market Timer Frank Kollar
April 1, 2008 (FinancialWire) (By Frank Kollar)
Shares of the ETF Pharmaceutical HLDRS (AMEX: PPH) have been considerably weaker than the stock market in 2008, and that is saying something of late.
The stock market hit panic lows back on January 22 and has since been recovering in most sectors. But Pharmaceutical HLDRS did not recover, and has since lost another 7% based on Monday’s March 31 close.
Monday’s close was also a gap down day that has placed Pharmaceutical HLDRS in danger of reaching, and possibly breaking, it’s March 17 closing correction lows at $68.85.
If Pharmaceutical HLDRS does break below, and close below $68.85, short positions could be considered, using a price 5% above the March 17 lows as a buy stop. For now, we would not consider a bullish position at all.
Kollar’s research has shown that the financial markets are in tradable trends approximately 80 percent of the time. FibTimer strategies define trends and trade them in both advancing and declining markets. Caring nothing about what newscasters say or what the latest economic indicator predicts, trends are where the profits are, and that is where FibTimer is.
Kollar is editor and chief analyst at FibTimer.com (http://www.fibtimer.com) which offers market timing strategies for S&P and Nasdaq index fund traders, as well as bond, gold, small cap, sector, ETF and stock trading strategies.
Go to previous Press Releases & Trading Notes.
Note: These Press Releases are short term in nature. They may or may not reflect the same position as current subscriber reports which typically have longer time frames.
© Copyright 1996-2008, Kollar Market Analytics, Inc., All Rights Reserved.
FibTimer reports may not be redistributed without permission. These Trading Notes however may be distributed without permission.
Disclaimer: The financial markets are risky. Investing is risky. Past performance
does not guarantee future performance. The foregoing has been prepared solely
for informational purposes and is not a solicitation, or an offer to buy or sell
any security. Opinions are based on historical research and data believed reliable,
but there is no guarantee that future results will be profitable. |